Reaching Precision in Cancer Therapy Through Patient-Derived MicroOrganoSpheres, Flow Cytometry Analysis, and Molecular Profiling

Precision medicine aims to match the right therapy to the right patient at the right time, improving efficacy and reducing side effects. In this webinar, Dr. Hsu discusses his work to develop personalized treatments for gastrointestinal (GI) cancer patients by creating patient-derived tumor models of cancer (PDMC) that predict how well a patient will respond to therapy. The approach includes a new miniature MicroOrganoSphere™ (MOS™) 3-D tissue model. In his work, Dr. Hsu utilizes the SH800 Cell Sorter to analyze and validate MOS and 10x Genomics’ Single Cell 3′ chemistry to perform molecular profiling of these clinical samples. Dr. Hsu’s promising technology is currently undergoing a clinical trial for colorectal cancer at Duke University.

 

 

 

Oncologists, researchers, pharmaceutical professionals, clinicians, regulatory experts, and patient advocates interested in precision medicine and cancer care.